[1]
Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, Amagai M. Pemphigus. Nature reviews. Disease primers. 2017 May 11:3():17026. doi: 10.1038/nrdp.2017.26. Epub 2017 May 11
[PubMed PMID: 28492232]
[2]
Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clinics in dermatology. 2014 May-Jun:32(3):364-75. doi: 10.1016/j.clindermatol.2013.11.003. Epub 2013 Nov 22
[PubMed PMID: 24767184]
[3]
Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. International journal of dermatology. 2009 Feb:48(2):162-9. doi: 10.1111/j.1365-4632.2009.03995.x. Epub
[PubMed PMID: 19200194]
[4]
Kelly S, Schifter M, Fulcher DA, Lin MW. Paraneoplastic pemphigus: two cases of intra-abdominal malignancy presenting solely as treatment refractory oral ulceration. The Journal of dermatology. 2015 Mar:42(3):300-4. doi: 10.1111/1346-8138.12753. Epub 2014 Dec 30
[PubMed PMID: 25557248]
Level 3 (low-level) evidence
[5]
Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. International journal of dermatology. 2011 Aug:50(8):905-14. doi: 10.1111/j.1365-4632.2011.04868.x. Epub
[PubMed PMID: 21781058]
[6]
Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H 3rd, Mutasim D, Ariss-Abdo L. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. The New England journal of medicine. 1990 Dec 20:323(25):1729-35
[PubMed PMID: 2247105]
[7]
Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, Webber RJ, Pittelkow MR, Lynch PJ, Grando SA. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Archives of dermatology. 2001 Feb:137(2):193-206
[PubMed PMID: 11176692]
[8]
Yong AA, Tey HL. Paraneoplastic pemphigus. The Australasian journal of dermatology. 2013 Nov:54(4):241-50. doi: 10.1111/j.1440-0960.2012.00921.x. Epub 2012 Jul 3
[PubMed PMID: 22759072]
[9]
Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral oncology. 2004 Jul:40(6):553-62
[PubMed PMID: 15063382]
[10]
Kartan S, Shi VY, Clark AK, Chan LS. Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment. American journal of clinical dermatology. 2017 Feb:18(1):105-126. doi: 10.1007/s40257-016-0235-z. Epub
[PubMed PMID: 27878477]
[11]
Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clinical reviews in allergy & immunology. 2018 Feb:54(1):1-25. doi: 10.1007/s12016-017-8662-z. Epub
[PubMed PMID: 29313220]
[12]
Akel R, Fakhri G, Salem R, Boulos F, Habib K, Tfayli A. Paraneoplastic Pemphigus as a First Manifestation of an Intra-Abdominal Follicular Dendritic Cell Sarcoma: Rare Case and Review of the Literature. Case reports in oncology. 2018 May-Aug:11(2):353-359. doi: 10.1159/000489602. Epub 2018 May 31
[PubMed PMID: 29928216]
Level 3 (low-level) evidence
[13]
Su Z, Liu G, Liu J, Fang T, Zeng Y, Zhang H, Yang S, Wang Y, Zhang J, Wei J, Li Y, Guo Y. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma: report of a case and review of literature. International journal of clinical and experimental pathology. 2015:8(10):11983-94
[PubMed PMID: 26722384]
Level 3 (low-level) evidence
[14]
Lim JM, Lee SE, Seo J, Kim DY, Hashimoto T, Kim SC. Paraneoplastic Pemphigus Associated with a Malignant Thymoma: A Case of Persistent and Refractory Oral Ulcerations Following Thymectomy. Annals of dermatology. 2017 Apr:29(2):219-222. doi: 10.5021/ad.2017.29.2.219. Epub 2017 Mar 24
[PubMed PMID: 28392652]
Level 3 (low-level) evidence
[15]
Wong KC, Ho KK. Pemphigus with pemphigoid-like presentation, associated with squamous cell carcinoma of the tongue. The Australasian journal of dermatology. 2000 Aug:41(3):178-80
[PubMed PMID: 10954991]
[16]
Hayanga AJ, Lee TM, Pannucci CJ, Knipp BS, Olsen SH, Wang SC, Napolitano LM. Paraneoplastic pemphigus in a burn intensive care unit: case report and review of the literature. Journal of burn care & research : official publication of the American Burn Association. 2010 Sep-Oct:31(5):826-9. doi: 10.1097/BCR.0b013e3181eed4b4. Epub
[PubMed PMID: 20683196]
Level 3 (low-level) evidence
[17]
Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, Mascaro JM Jr, Nousari HC. Paraneoplastic pemphigus in children and adolescents. The British journal of dermatology. 2002 Oct:147(4):725-32
[PubMed PMID: 12366419]
[18]
Martel P, Loiseau P, Joly P, Busson M, Lepage V, Mouquet H, Courville P, Flageul B, Charron D, Musette P, Gilbert D, Tron F. Paraneoplastic pemphigus is associated with the DRB1*03 allele. Journal of autoimmunity. 2003 Feb:20(1):91-5
[PubMed PMID: 12604316]
[19]
Liu Q, Bu DF, Li D, Zhu XJ. Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. The British journal of dermatology. 2008 Mar:158(3):587-91
[PubMed PMID: 18070207]
[20]
Lane JE, Woody C, Davis LS, Guill MF, Jerath RS. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature. Pediatrics. 2004 Oct:114(4):e513-6
[PubMed PMID: 15466078]
Level 3 (low-level) evidence
[21]
Ogawa H, Sakuma M, Morioka S, Kitamura K, Sasai Y, Imamura S, Inaba Y. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. Journal of dermatological science. 1995 Mar:9(2):136-41
[PubMed PMID: 7772576]
[22]
Paolino G,Didona D,Magliulo G,Iannella G,Didona B,Mercuri SR,Moliterni E,Donati M,Ciofalo A,Granata G,Ranuzzi P,Falasca V,Calvieri S, Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy. International journal of molecular sciences. 2017 Nov 26;
[PubMed PMID: 29186863]
[23]
Tsuchisaka A,Numata S,Teye K,Natsuaki Y,Kawakami T,Takeda Y,Wang W,Ishikawa K,Goto M,Koga H,Sogame R,Ishii N,Takamori S,Hoshino T,Brandt O,Pas HH,Fujiwara S,Hashimoto T, Epiplakin Is a Paraneoplastic Pemphigus Autoantigen and Related to Bronchiolitis Obliterans in Japanese Patients. The Journal of investigative dermatology. 2016 Feb;
[PubMed PMID: 26802236]
[24]
Ohzono A, Sogame R, Li X, Teye K, Tsuchisaka A, Numata S, Koga H, Kawakami T, Tsuruta D, Ishii N, Hashimoto T. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. The British journal of dermatology. 2015 Dec:173(6):1447-52. doi: 10.1111/bjd.14162. Epub 2015 Nov 14
[PubMed PMID: 26358412]
Level 3 (low-level) evidence
[25]
Numata S, Teye K, Tsuruta D, Sogame R, Ishii N, Koga H, Natsuaki Y, Tsuchisaka A, Hamada T, Karashima T, Nakama T, Furumura M, Ohata C, Kawakami T, Schepens I, Borradori L, Hashimoto T. Anti-α-2-macroglobulin-like-1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus. The Journal of investigative dermatology. 2013 Jul:133(7):1785-93. doi: 10.1038/jid.2013.65. Epub 2013 Feb 13
[PubMed PMID: 23407400]
[26]
Schepens I, Jaunin F, Begre N, Läderach U, Marcus K, Hashimoto T, Favre B, Borradori L. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PloS one. 2010 Aug 18:5(8):e12250. doi: 10.1371/journal.pone.0012250. Epub 2010 Aug 18
[PubMed PMID: 20805888]
[27]
Amber KT, Valdebran M, Grando SA. Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus. Autoimmunity reviews. 2018 Oct:17(10):1002-1010. doi: 10.1016/j.autrev.2018.04.008. Epub 2018 Aug 11
[PubMed PMID: 30103046]
[28]
Li J, Bu DF, Huang YC, Zhu XJ. Role of autoantibodies against the linker subdomains of envoplakin and periplakin in the pathogenesis of paraneoplastic pemphigus. Chinese medical journal. 2009 Mar 5:122(5):486-95
[PubMed PMID: 19323896]
[29]
Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Archives of dermatology. 1992 Aug:128(8):1091-5
[PubMed PMID: 1497365]
[31]
Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, Beylot-Barry M, D'incan M, Martel P, Lauret P, Tron F. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. Journal of the American Academy of Dermatology. 2000 Oct:43(4):619-26
[PubMed PMID: 11004616]
[32]
Solimani F, Maglie R, Pollmann R, Schmidt T, Schmidt A, Ishii N, Tackenberg B, Kirschbaum A, Didona D, Pickert J, Eming R, Hashimoto T, Hertl M. Thymoma-Associated Paraneoplastic Autoimmune Multiorgan Syndrome-From Pemphigus to Lichenoid Dermatitis. Frontiers in immunology. 2019:10():1413. doi: 10.3389/fimmu.2019.01413. Epub 2019 Jun 21
[PubMed PMID: 31293579]
[33]
Wieczorek M, Czernik A. Paraneoplastic pemphigus: a short review. Clinical, cosmetic and investigational dermatology. 2016:9():291-295
[PubMed PMID: 27729809]
[34]
Meyers SJ, Varley GA, Meisler DM, Camisa C, Wander AH. Conjunctival involvement in paraneoplastic pemphigus. American journal of ophthalmology. 1992 Nov 15:114(5):621-4
[PubMed PMID: 1443026]
[35]
Kim JH, Kim SC. Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa. Frontiers in immunology. 2019:10():1259. doi: 10.3389/fimmu.2019.01259. Epub 2019 Jun 4
[PubMed PMID: 31214197]
[36]
Broussard KC, Leung TG, Moradi A, Thorne JE, Fine JD. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clinics in dermatology. 2016 Mar-Apr:34(2):205-13. doi: 10.1016/j.clindermatol.2015.11.006. Epub 2015 Dec 19
[PubMed PMID: 26903186]
[37]
Wade MS, Black MM. Paraneoplastic pemphigus: a brief update. The Australasian journal of dermatology. 2005 Feb:46(1):1-8; quiz 9-10
[PubMed PMID: 15670168]
[38]
Ouedraogo E, Gottlieb J, de Masson A, Lepelletier C, Jachiet M, Salle de Chou C, Galicier L, Bagot M, Chevret S, Bouaziz JD. Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults. Journal of the American Academy of Dermatology. 2019 Jun:80(6):1544-1549. doi: 10.1016/j.jaad.2018.03.043. Epub 2019 Apr 10
[PubMed PMID: 30981429]
[39]
Wang L, Deng H, Mao M. Paraneoplastic pemphigus and myasthenia gravis, associated with inflammatory pseudotumor-like follicular dendritic cell sarcoma: response to rituximab. Clinical case reports. 2016 Aug:4(8):797-9. doi: 10.1002/ccr3.625. Epub 2016 Jul 15
[PubMed PMID: 27525088]
Level 3 (low-level) evidence
[40]
Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmunity reviews. 2014 Apr-May:13(4-5):477-81. doi: 10.1016/j.autrev.2014.01.011. Epub 2014 Jan 11
[PubMed PMID: 24424192]
[41]
Poot AM, Diercks GF, Kramer D, Schepens I, Klunder G, Hashimoto T, Borradori L, Jonkman MF, Pas HH. Laboratory diagnosis of paraneoplastic pemphigus. The British journal of dermatology. 2013 Nov:169(5):1016-24. doi: 10.1111/bjd.12479. Epub
[PubMed PMID: 23796242]
[42]
Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Archives of dermatology. 1993 Jul:129(7):883-6
[PubMed PMID: 8323311]
[43]
Radoš J. Autoimmune blistering diseases: histologic meaning. Clinics in dermatology. 2011 Jul-Aug:29(4):377-88. doi: 10.1016/j.clindermatol.2011.01.007. Epub
[PubMed PMID: 21679865]
[44]
Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2010 Aug:8(8):598-606. doi: 10.1111/j.1610-0387.2010.07380.x. Epub 2010 Feb 18
[PubMed PMID: 20180886]
[45]
Powell JG, Grover RK, Plunkett RW, Seiffert-Sinha K, Sinha AA. Evaluation of a Newly Available ELISA for Envoplakin Autoantibodies for the Diagnosis of Paraneoplastic Pemphigus. Journal of drugs in dermatology : JDD. 2015 Oct:14(10):1103-6
[PubMed PMID: 26461820]
[46]
Probst C, Schlumberger W, Stöcker W, Recke A, Schmidt E, Hashimoto T, Zhu XJ, Zillikens D, Komorowski L. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clinica chimica acta; international journal of clinical chemistry. 2009 Dec:410(1-2):13-8. doi: 10.1016/j.cca.2009.08.022. Epub 2009 Sep 6
[PubMed PMID: 19737550]
[47]
Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, Chaumentin G, Chevrant-Breton J, Chosidow O, Crickx B, D'incan M, Dandurand M, Debarbieux S, Delaporte E, Dereure O, Doutre MS, Guillet G, Jullien D, Kupfer I, Lacour JP, Leonard F, Lok C, Machet L, Martin L, Paul C, Pignon JM, Robert C, Thomas L, Weiller PJ, Ferranti V, Gilbert D, Courville P, Houivet E, Benichou J, Joly P. Prognostic factors of paraneoplastic pemphigus. Archives of dermatology. 2012 Oct:148(10):1165-72
[PubMed PMID: 22801794]
[48]
Kikuchi T, Mori T, Shimizu T, Koda Y, Abe R, Kurihara Y, Funakoshi T, Yamagami J, Sato H, Tsunoda K, Amagai M, Okamoto S. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus. Annals of hematology. 2017 Jul:96(7):1221-1222. doi: 10.1007/s00277-017-3008-8. Epub 2017 Apr 26
[PubMed PMID: 28447163]
[49]
Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Deleuran M, d'Amore F. Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus. The British journal of dermatology. 2013 Aug:169(2):469-72. doi: 10.1111/bjd.12324. Epub
[PubMed PMID: 23517368]
[50]
Hohwy T, Bang K, Steiniche T, Peterslund NA, d'Amore F. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. European journal of haematology. 2004 Sep:73(3):206-9
[PubMed PMID: 15287918]
Level 3 (low-level) evidence
[51]
McCuin JB, Hanlon T, Mutasim DF. Autoimmune bullous diseases: diagnosis and management. Dermatology nursing. 2006 Feb:18(1):20-5
[PubMed PMID: 16550892]
[52]
Powers JG, Higham C, Broussard K, Phillips TJ. Wound healing and treating wounds: Chronic wound care and management. Journal of the American Academy of Dermatology. 2016 Apr:74(4):607-25; quiz 625-6. doi: 10.1016/j.jaad.2015.08.070. Epub
[PubMed PMID: 26979353]
[53]
Murrell DF, Peña S, Joly P, Marinovic B, Hashimoto T, Diaz LA, Sinha AA, Payne AS, Daneshpazhooh M, Eming R, Jonkman MF, Mimouni D, Borradori L, Kim SC, Yamagami J, Lehman JS, Saleh MA, Culton DA, Czernik A, Zone JJ, Fivenson D, Ujiie H, Wozniak K, Akman-Karakaş A, Bernard P, Korman NJ, Caux F, Drenovska K, Prost-Squarcioni C, Vassileva S, Feldman RJ, Cardones AR, Bauer J, Ioannides D, Jedlickova H, Palisson F, Patsatsi A, Uzun S, Yayli S, Zillikens D, Amagai M, Hertl M, Schmidt E, Aoki V, Grando SA, Shimizu H, Baum S, Cianchini G, Feliciani C, Iranzo P, Mascaró JM Jr, Kowalewski C, Hall R, Groves R, Harman KE, Marinkovich MP, Maverakis E, Werth VP. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology. 2020 Mar:82(3):575-585.e1. doi: 10.1016/j.jaad.2018.02.021. Epub 2018 Feb 10
[PubMed PMID: 29438767]
[54]
Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, Anhalt GJ. The mechanism of respiratory failure in paraneoplastic pemphigus. The New England journal of medicine. 1999 May 6:340(18):1406-10
[PubMed PMID: 10228191]
[55]
Zhang J, Qiao QL, Chen XX, Liu P, Qiu JX, Zhao H, Zhao JX, Liu YC, Wan YL. Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases. Journal of cancer research and clinical oncology. 2011 Feb:137(2):229-34. doi: 10.1007/s00432-010-0874-z. Epub
[PubMed PMID: 20390428]
Level 2 (mid-level) evidence
[56]
Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. The British journal of dermatology. 2003 Dec:149(6):1143-51
[PubMed PMID: 14674890]
[57]
Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatologic clinics. 2011 Oct:29(4):607-12. doi: 10.1016/j.det.2011.06.016. Epub 2011 Aug 15
[PubMed PMID: 21925005]